BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

Significance: PARP inhibition is a potential strategy for treating patients with gastric cancer with mutated BRCA2 or homologous repair deficiency, including patients with familial intestinal gastric cancer, for whom BRCA2 germline testing should be recommended.

Citing Articles

Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node.

Xia Y, Huang Y, Liu Z, Song S, Wang Y, Luo J Front Immunol. 2025; 16:1548102.

PMID: 39925800 PMC: 11802514. DOI: 10.3389/fimmu.2025.1548102.

Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives.

Lordick F, Rha S, Muro K, Yong W, Obermannova R Cancers (Basel). 2024; 16(19).

PMID: 39409957 PMC: 11475804. DOI: 10.3390/cancers16193337.

Tumour mutational burden: clinical utility, challenges and emerging improvements.

Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altburger C Nat Rev Clin Oncol. 2024; 21(10):725-742.

PMID: 39192001 DOI: 10.1038/s41571-024-00932-9.

Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review.

Ratti M, Orlandi E, Toscani I, Vecchia S, Anselmi E, Hahne J Cancers (Basel). 2024; 16(15).

PMID: 39123420 PMC: 11311890. DOI: 10.3390/cancers16152692.

Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapy.

Ichikawa H, Aizawa M, Kano Y, Hanyu T, Muneoka Y, Hiroi S Gastric Cancer. 2024; 27(6):1273-1286.

PMID: 39110344 DOI: 10.1007/s10120-024-01542-1.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Bang Y, Im S, Lee K, Cho J, Song E, Lee K . Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. J Clin Oncol. 2015; 33(33):3858-65. DOI: 10.1200/JCO.2014.60.0320. View

Apicella M, Migliore C, Capeloa T, Menegon S, Cargnelutti M, Degiuli M . Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. Oncogene. 2016; 36(9):1200-1210. DOI: 10.1038/onc.2016.283. View

Waddell N, Pajic M, Patch A, Chang D, Kassahn K, Bailey P . Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518(7540):495-501. PMC: 4523082. DOI: 10.1038/nature14169. View

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Wang K, Li M, Hakonarson H . ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164. PMC: 2938201. DOI: 10.1093/nar/gkq603. View

Martin S, Matsubayashi H, Rogers C, Philips J, Couch F, Brune K . Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene. 2005; 24(22):3652-6. DOI: 10.1038/sj.onc.1208411. View

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

Favero F, Joshi T, Marquard A, Birkbak N, Krzystanek M, Li Q . Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol. 2014; 26(1):64-70. PMC: 4269342. DOI: 10.1093/annonc/mdu479. View

10.

Clark N, Hafner M, Kouril M, Williams E, Muhlich J, Pilarczyk M . GRcalculator: an online tool for calculating and mining dose-response data. BMC Cancer. 2017; 17(1):698. PMC: 5655815. DOI: 10.1186/s12885-017-3689-3. View

11.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C . A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2012; 1(6):508-23. DOI: 10.1158/2159-8290.CD-11-0109. View

12.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

13.

Spies M, Fishel R . Mismatch repair during homologous and homeologous recombination. Cold Spring Harb Perspect Biol. 2015; 7(3):a022657. PMC: 4355274. DOI: 10.1101/cshperspect.a022657. View

14.

Hafner M, Niepel M, Chung M, Sorger P . Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods. 2016; 13(6):521-7. PMC: 4887336. DOI: 10.1038/nmeth.3853. View

15.

Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F . Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018; 4:16. PMC: 6028448. DOI: 10.1038/s41523-018-0066-6. View

16.

Janjigian Y, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O . The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021; 600(7890):727-730. PMC: 8959470. DOI: 10.1038/s41586-021-04161-3. View

17.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

18.

Ballabeni A, Zamponi R, Moore J, Helin K, Kirschner M . Geminin deploys multiple mechanisms to regulate Cdt1 before cell division thus ensuring the proper execution of DNA replication. Proc Natl Acad Sci U S A. 2013; 110(30):E2848-53. PMC: 3725105. DOI: 10.1073/pnas.1310677110. View

19.

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

20.

Secrier M, Li X, de Silva N, Eldridge M, Contino G, Bornschein J . Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016; 48(10):1131-41. PMC: 5957269. DOI: 10.1038/ng.3659. View